The role of oxidized lipoproteins (ox-lipids) in the pathogenesis of cardiovascular disease (CVD) in chronic HIV infection remains poorly defined.
A5260s enrolled 328 HIV-infected antiretroviral treatment (ART) naïve participants without known CVD or diabetes mellitus. All participants were randomized to receive tenofovir disoproxil fumarate-emtricitabine plus atazanavir/ritonavir (ATV/r), darunavir/r (DRV/r), or raltegravir (RAL) as part of a large prospective clinical trial (A5257). The present analyses include 234 virologically suppressed subjects who achieved plasma HIV-1 RNA <50 copies/ml by week 24 and maintained through 3 years. Carotid intima media thickness (CIMT) was evaluated at study entry and then annually. Oxidized low-density lipoprotein (LDLox) was determined by ELISA and oxidized high-density lipoprotein (HDLox) by a novel biochemical assay. Ox-lipid fold changes from baseline were examined after 24 and 96 weeks (ratios of 1.0 indicate no change); pairwise treatment group comparisons used Wilcoxon rank-sum tests with p-values adjusted for false discovery rate control. Association analyses of ox-lipids with rate of CIMT progression over 3 years used mixed effects linear regression with ox-lipids categorized by quartiles.
Participant characteristics of this virologically suppressed cohort were similar to the full substudy population. The cohort was 90% men, 48% white, 29% black, 19% Hispanic; median age was 36 years. At baseline, 12% had a 10 year risk of hard coronary heart disease >6%;13% had metabolic syndrome; prevalence of carotid lesions was low (9%). Median CD4+ cell count and HIV-1 RNA was 338 cells/mm3 and 4.6 log10 copies/ml, respectively. Over 96 weeks, HDLox declined with ATV/r and DRV/r; LDLox increased in all groups. Treatment group differences were apparent only with HDLox at week 24 between RAL and ATV/r, and RAL and DRV/r (p<0.025). Associations between the CIMT rate of progression and baseline and on-treatment ox-lipids were not apparent (p>0.40, Table). These results remained consistent upon further adjustment for lipoprotein concentration.
Contrary to prior limited data that oxidized lipoproteins are associated with subclinical atherosclerosis, we did not find evidence of an association between early on-treatment levels of HDLox or LDLox and the rate of IMT progression estimated over 3 years on ART. Larger studies involving other CVD endpoints are needed to further study the role of ox-lipids in HIV-associated CVD.